neosaxitoxin + bupivacaine + epinephrine

**Neosaxitoxin + bupivacaine + epinephrine** is an investigational combination for local anesthesia designed to produce prolonged and potent sensory and pain blockade. Neosaxitoxin is a site 1 sodium channel blocker (saxitoxin analog), bupivacaine is an amino amide local anesthetic, and epinephrine acts as a vasoconstrictor to reduce systemic absorption and toxicity. In preclinical and Phase 1 studies, the combination leads to significantly prolonged duration and intensity of sensory blockade compared to individual agents or their binary combinations, with improved safety and reduced systemic adverse effects. The aim is to create a safer, long-lasting local anesthetic for clinical procedures and postsurgical analgesia[1][2][3].

Other names

NeoSTX + bupivacaine + epinephrineneosaxitoxin and bupivacaine and epinephrine